Drug intelligence / Profile preview

Lactobacillin

Development stage: Unknown
Lead developer: National Institutes of Health
Administration: Oral

Overview

Lactobacillin is a biologic product derived from the fermentation of skim milk by Lactobacillus acidophilus. It is classified as a digestive non-prescription drug in China. Its mechanism of action involves modulating the intestinal environment by forming a protective barrier, stimulating local immune responses, selectively inhibiting pathogenic bacteria, promoting beneficial flora, regulating intestinal electrolyte and water balance, and enhancing digestive function. It is primarily used for various gastrointestinal disorders and is currently under investigation for the prevention and treatment of oral mucositis.

Brand names: Lacidophilin TabletsLactoGuardProBioActiveSymbiotex
Other names: 乳酸菌素乳酸菌素片

Beyond the preview

Go deeper on Lactobacillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillin.

Explore the full profile